Nls pharmaceutics announces $4 million private placement and conversion of existing short-term notes

Zurich, switzerland / accesswire / october 3, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into definitive agreements with investors, alongside participation from the company's chairman of the board of directors, ronald hafner, and george apostol, the company's recently appointed chief medical officer, for the purchase and sale on a private placement basis of 5,194,802 of its common shares, and warrants to purchase up to 2,597,401 common shares (the common shares and warrants, together the "securities"), resulting in total gross proceeds of approximately $4 million before deducting placement agent commissions and other estimated offering expenses.
NLSP Ratings Summary
NLSP Quant Ranking